Bone Growth Stimulator Market Assessment, By Product [Bone Growth Stimulator Device, Platelet-Rich Plasma, Bone Morphogenetic Proteins], By Application [Spinal Fusion Surgeries, Orthopedic Trauma Surgeries, Delayed Union and Nonunion Bone Fracture, Others

Bone Growth Stimulator Market Assessment, By Product [Bone Growth Stimulator Device, Platelet-Rich Plasma, Bone Morphogenetic Proteins], By Application [Spinal Fusion Surgeries, Orthopedic Trauma Surgeries, Delayed Union and Nonunion Bone Fracture, Others], By End-user [Hospitals, Specialized Orthopedic Clinics, Ambulatory Surgical Centers], By Region, Opportunities and Forecast, 2018-2032F

Global bone growth stimulator market is projected to witness a CAGR of 5.10% during the forecast period 2025-2032, growing from USD 2.06 billion in 2024 to USD 3.07 billion in 2032. The global bone growth stimulator market is expected to grow robustly during the forecast period owing to the increasing prevalence of orthopedic conditions and the growing aging population.

Bone growth stimulators are the products used for bone healing, enhancing the natural regenerative process. Such devices are common in patients with delayed healing or impaired healing of bone tissue, such as fractures, spinal fusions, or osteoporosis. These medical devices transmit electrical or ultrasonic signals to the affected region, stimulating biological processes and encouraging bone growth. In addition to improved technological advancements, such as the development of non-invasive and portable devices, they enhance patient compliance and subsequently expand their usage. These factors, coupled with the increasing incidence of sports injuries and spinal fusion surgeries, act as a favorable driver, considering the importance of these devices in facilitating bone healing. Favorable reimbursement policies and the growing consciousness of healthcare providers and patients drive market growth.

For instance, in September 2024, Orthofix Medical Inc., a global leader in medical technology, announced new data supporting its Pulsed Electromagnetic Field (PEMF) therapy for enhancing fusion rates in lumbar spine surgeries. Patients using the SpinalStim device showed high fusion success, improved pain relief, and better quality of life, even with pseudarthrosis risk factors.

Increasing Prevalence of Orthopedic Disorders Boosts Market Growth

Rising cases of orthopedic disorders are witnessing a significant growth driver for the bone growth stimulator market. The incidence of bone-related conditions, such as fractures, osteoporosis, and delayed or non-union fractures, continues to increase with the world's aging population. This increasing burden of orthopedic disorders is providing momentum to the adoption of bone growth stimulators, increasingly recognized for the potent acceleration of bone healing and improvement of patient outcomes and spreading awareness and more healthcare providers adopting them in treatment plans for the market for further growth.

For instance, in November 2023, Nevro Corp. acquired Vyrsa Technologies, Inc., a medical technology company focused on minimally invasive solutions for chronic sacroiliac joint pain. The USD 40 million acquisition, with potential milestone-based payments of up to USD 35 million, strengthens Nevro's position in the more than USD 2 billion United States sacroiliac joint fusion market. Vyrsa’s FDA-cleared portfolio of fusion devices offers physicians tailored solutions for improved patient outcomes in sacroiliac joint procedures.

Technological Advancements Fuel the Bone Growth Stimulator Market

Technological advancement is a key driver of the bone growth stimulator market. Novel technological innovation has led to the development of more effective and non-invasive devices with user-friendly interfaces for healthcare providers and patients. Advanced ultrasound and electrical stimulation technologies have led to portable and efficient bone growth stimulators with minimal discomfort but targeted treatments. These advances increase ease of use, boosting patient adherence and enlarging the market size. Moreover, including wearable devices and smartphone apps has helped in telemonitoring and developing individualized treatment plans, making it easier for healthcare providers to monitor the patient's progress. Such technological advancements are improving the therapeutic effect of bone healing and cutting down the cost of treatment, thus enlarging access to bone growth stimulators. For instance, in June 2024, Johnson & Johnson Services, Inc., announced that DePuy Synthes, the Orthopedics company of Johnson & Johnson Services, Inc., has received FDA 510(k) clearance for the VELYS Robotic-Assisted Solution in Unicompartmental Knee Arthroplasty (UKA). Building on its Total Knee Arthroplasty (TKA) platform, used in 55,000+ procedures, the UKA solution supports precise implant placement without a CT scan and integrates with the SIGMA HP Knee System.

Spinal Fusion Surgeries Segment to Dominate the Bone Growth Stimulator Market

The global bone growth stimulator market is likely to be dominated by the spinal fusion surgery segment, as these devices play a critical role in the healing process following a spinal fusion procedure. Those surgeries, generally categorized as common treatments for degenerative disc disease, scoliosis, and spinal fractures, require the use of bone growth stimulators to promote bone healing and ensure successful outcomes. These devices accelerate bone fusion, reduce the chances of nonunion fractures, and eventually impact recovery time generally. These factors make it an important part of postoperative care. The growing rate of spinal disorders and the increased number of spinal fusion procedures have driven the demand for bone growth stimulators in this segment.

For instance, in June 2022, Aurora Spine Corporation received FDA 510(k) clearance for its DEXA SOLO-L spinal fusion system, a 3D-printed standalone anterior lumbar interbody fusion (ALIF) device. Part of Aurora's patented DEXA Technology Platform, it is the first bone density-matched implant designed to match a patient’s bone quality. The device supports anterior and lateral lumbar interbody fusion procedures and is the first color-coded, bone-mimicking implant on the market.

North America Dominates the Bone Growth Stimulator Market

North America is expected to emerge as the leading region in the bone growth stimulator market. This top leadership is due to its good healthcare infrastructure and advanced adoption of innovative technologies. Rising cases of orthopedic diseases, which include fractures, osteoporosis, and spinal disorders, are driving the demand for effective products in bone healing. Favorable reimbursement policies and facilitation through regulations are the other main reasons driving the growth of the North American market, which is increasing patients' access to bone growth stimulators. The rate of surgical procedures, such as spinal fusion surgeries, in this region is high. The use of bone growth stimulants improves the results of such therapeutic procedures. Technological advancements in the form of non-invasive and portable devices have also increased the pace of acceptance of these devices in the market.

For instance, in April 2024, Xstim, Inc., received approval from the United States Food and Drug Administration Premarket Application (PMA) for its Xstim Spine Fusion Stimulator, a capacitively coupled device designed to enhance bone healing after spinal fusion surgery. The non-invasive device features an intuitive interface and sleek design, prioritizing patient comfort and usability.

Future Market Scenario (2025-2032F)

The future scenario of the global bone growth promoter market is promising, as technological advancements and growing awareness among healthcare professionals drive patient demand for effective bone healing. Considering the increasing prevalence of orthopedic diseases and the aging of the global population, the demand for innovative and non-invasive treatments will continue to grow. Advancements in research and development lead to more economical, portable, and practical devices, and thus market growth. With improving reimbursement systems across the region and growing awareness towards bone growth promoters, the market is expected to grow steadily, positioning itself as a key segment in orthopedic and postoperative care.

For instance, in February 2024, Zeda Tech Inc., a global technology solutions company, acquired The Orthopaedic Implant Company, a leader in cost-effective orthopedic implants. The acquisition enhances Zeda’s ability to produce value-based trauma implants using advanced manufacturing technologies, expanding global access to high-quality, affordable care.

Key Players Landscape and Outlook

The bone growth stimulator market is segmented into devices used for bone stimulation and services provided to patients for bone healing. The service market is fragmented due to many local and global players, while medical device manufacturers dominate the market. Recent market activities include product launches, new treatment center setups, and strategic business agreements such as mergers and acquisitions.

For instance, in January 2024, Enovis Corporation completed the acquisition of LimaCorporate S.p.A., a global orthopedic leader specializing in implant solutions. The acquisition enhances Enovis Corporation's orthopedic reconstruction portfolio, adding advanced technologies like 3D-printed Trabecular Titanium implants and comprehensive revision offerings. This positions Enovis as a USD 1 billion innovator in the fast-growing extreme market.